HISTORY

Syntex is an Argentine company that elaborates active ingredients from biological and semi-synthetic origins for Human and Veterinary Pharmaceutical Industry since 1935.


Syntex maintains its global leadership as a pharmaceutical supplier, presenting innovative products and permanently investing in technology as well as productive capacity in its plants. 

Syntex counts with around 200 employees and more than 2000 sqm of productive area for active pharmaceutical ingredients and 1000 sqm for veterinary specialties.

Syntex trades four active ingredients in Argentina and over the world: Heparins, Chondroitins, Hormones and Ferric Compounds as well as an ample Veterinary Specialties line.


Syntex produces different active ingredients in facilities exclusively dedicated to each product family and based on a solid and traceable documentation.


Between 2004 and 2006 the areas for the production of chondroitin sulfate and heparin were completely renovated to meet new market standards.

See below the milestones for Syntex heparin production:

1961

1986

1987

1990

1992

2001

2004

2006

2008

2011

2012

2013

2014

Large scale Heparin production.

Development of Heparin semi-synthetic polysaccharide derivatives. First depolymerization studies.

Suleparoide (INN) production, first semi-synthetic polysaccharide. Technological development under patent.

Low Molecular Weight Heparin.  Technological development under patent.

Semi-synthetic Heparin, Dermatan and Chondroitin Sulphate derivatives and analogues.

Low Molecular Weight Chondroitin Sulphate Triethanolamine Salt production and Low Molecular Weight Heparin industrial production.

Patenting of Modified Heparin new fragments for topic administration in antithrombotic use.

Opening of Heparin new plant in compliance with cGMP

Low Molecular Weight Heparin (Parnaparin) plant approval by the Japanese Health Regulatory Authority.

Renewal of the Heparin plant was, adding new manufacturing areas.

Jordan FDA plant approval

Obtaining of the HALAL certification

FDA inspection of the Heparin site.

Currently: working on the expansion of Heparin production capacity.